Harvard Bioscience (HBIO) Earnings Analysis

Harvard Bioscience (HBIO) next reports earnings on 2026-08-10, consensus EPS -0.21 USD. Last quarter (2026-03-12) it missed with EPS -0.01 USD vs 0.35 USD est (-102.9%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -2.79.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does HBIO next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.21 USD
Revenue estimate0.02B

HBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-0.01 USD0.35 USD-102.9%Miss
2025-08-11-0.01 USD-0.025 USD+60%Beat
2025-05-12-0.01 USD-0.04 USD+75%Beat
2025-03-120.06 USD0.05 USD+20%Beat
2024-11-07-0.02 USD-0.0073 USD-174%Miss

Beat rate: 3/5 (60%) over reported quarters with consensus data.

HBIO valuation and analyst view

Trailing P/E-2.79
Trailing EPS-2.18735 USD
Price / book2.73
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)
Avg price target6 USD

Related research pages

Frequently asked questions

When is Harvard Bioscience (HBIO)'s next earnings date?

Harvard Bioscience is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.21 USD and revenue estimate of 0.02B.

Did HBIO beat earnings last quarter?

In its 2026-03-12 report, HBIO posted EPS of -0.01 USD versus a 0.35 USD estimate — a miss of 102.9%.

What is HBIO's earnings track record?

Over the last 5 reported quarters with consensus data, HBIO beat estimates 3 times (60%).

What is HBIO's current P/E ratio and EPS?

HBIO trades at a trailing P/E of -2.79 on trailing EPS of -2.1873463000223565 USD.

What do analysts rate HBIO?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 6 USD.